Subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings' traditional Chinese medicine division has obtained a notification letter for drug clinical trial approval.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332. SH) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Chinese Medicine Modern Pharmaceutical Co., Ltd. (referred to as "Guangzhou Baiyunshan Pharmaceutical Holdings Chinese Medicine") has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for the drug LBZ-18, LBZ-18 oral suspension. In accordance with the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the clinical trial applications for LBZ-18 oral suspension (CXZL2400071) and LBZ-18 (CXZL2400070) submitted on October 28, 2024, meet the relevant requirements for drug registration. Upon further improvement of the clinical trial protocol, the formulation of this drug is approved for conducting clinical trials for cancer-related fatigue.